An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinib in Patients with Early Diffuse Cutaneous Systemic Sclerosis An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinibin Pa ...
An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinib in Patients with Early Diffuse Cutaneous Systemic Sclerosis An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinibin Pa ...